A record amount of money is spent developing new drugs, but drug approval rates are declining and many fatal diseases are left untreated. A big reason behind this is often times current drug testing methods including animal testing don’t accurately predict the human response to drugs. What if we can 3D print living human tissue […]
VANCOUVER, BC, Canada – March 15, 2017 – Aspect Biosystems Ltd., a leader in the field of 3D bioprinting and tissue engineering, is pleased to announce a research collaboration with University of Manitoba Professor Adrian West. The research collaboration is supported by the Canada Foundation for Innovation’s (CFI) John R. Evans Leaders Fund (JELF). The […]
March 13, 2017 | Global News BC | “A B.C. company is using 3-D printing to create human tissue for testing life-saving drugs, and has its sights set even higher in the future. Linda Aylesworth reports.”
March 3, 2017 | Ready to Rocket | Aspect Biosystems has been selected for Ready to Rocket’s Life Sciences List 2017. Ready to Rocket highlights British Columbia technology companies with high growth potential in the life sciences, digital health, cleantech and ICT sectors. This is Aspect’s third year on the list. See full press release here.
VANCOUVER, BC, Canada – February 20, 2017 – Aspect Biosystems Ltd., a privately held biotechnology company operating at the leading edge of 3D bioprinting and tissue engineering, is pleased to announce that Dr. Peter Zandstra will join the company as an advisor. “We are delighted to welcome Peter Zandstra to our team of advisors,” says […]
January 28, 2017 | Vancouver Sun | Read this article in the Vancouver Sun to hear about the applications of our 3D bioprinting technology, our latest deal with Johnson & Johnson to develop 3D bioprinted meniscus tissue, and CEO Tamer Mohamed’s take on the British Columbia tech sector.